Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,026,589
  • Shares Outstanding, K 53,701
  • Annual Sales, $ 1,555 M
  • Annual Income, $ 305,100 K
  • 60-Month Beta 0.91
  • Price/Sales 1.97
  • Price/Cash Flow 6.18
  • Price/Book 2.20
Trade EBS with:

Options Overview

Details
  • Implied Volatility 47.40%
  • Historical Volatility 23.93%
  • IV Percentile 23%
  • IV Rank 10.13%
  • IV High 109.35% on 11/03/20
  • IV Low 40.41% on 09/17/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 176
  • Volume Avg (30-Day) 203
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 2,177
  • Open Int (30-Day) 2,499

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 2.29
  • Number of Estimates 2
  • High Estimate 2.43
  • Low Estimate 2.15
  • Prior Year 2.19
  • Growth Rate Est. (year over year) +4.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.87 +0.88%
on 09/20/21
65.09 -13.41%
on 08/30/21
-6.87 (-10.87%)
since 08/20/21
3-Month
55.87 +0.88%
on 09/20/21
68.03 -17.15%
on 07/29/21
-4.19 (-6.92%)
since 06/18/21
52-Week
55.07 +2.34%
on 05/11/21
127.20 -55.69%
on 02/16/21
-44.23 (-43.97%)
since 09/18/20

Most Recent Stories

More News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

EBS : 56.36 (-1.37%)
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence

Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.

AZN : 58.50 (+5.29%)
JNJ : 163.81 (-0.57%)
VRTX : 185.67 (-1.40%)
EBS : 56.36 (-1.37%)
/C O R R E C T I O N from Source -- Providence Therapeutics/

COMTEX_393326934/2669/2021-09-14T13:18:43

EBS : 56.36 (-1.37%)
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

COMTEX_393308853/2669/2021-09-14T07:58:29

EBS : 56.36 (-1.37%)
NYSE: EBS Investor Notice: Lawsuit against Emergent BioSolutions Inc announced by the Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Emergent BioSolutions Inc (NYSE: EBS) shares.

EBS : 56.36 (-1.37%)
Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

-- NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent's COVID-19 Human Immune Globulin (COVID-HIG), for potential treatment...

EBS : 56.36 (-1.37%)
Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investor conferences:

EBS : 56.36 (-1.37%)
EBS Long Term Investor Alert: Did You Acquire (EBS) Before April 24, 2020? - Johnson Fistel Continues its Investigation

Johnson Fistel, LLP is investigating potential claims on behalf of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS) against certain of its officers and directors.

EBS : 56.36 (-1.37%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Emergent BioSolutions, Peloton, and Vroom on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Emergent BioSolutions, Inc. (NYSE: EBS), Peloton Interactive, Inc. (NASDAQ:...

EBS : 56.36 (-1.37%)
PTON : 100.73 (-2.60%)
VRM : 24.13 (-0.45%)
New Strong Sell Stocks for August 2nd

ATTO, BLDP, NTB, CCJ and EBS have been added to the Zacks Rank #5 (Strong Sell) List on August 2, 2021.

CCJ : 21.31 (-5.12%)
BLDP : 15.06 (-4.92%)
EBS : 56.36 (-1.37%)
ATTO : 28.83 (-2.44%)
NTB : 31.49 (-2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining...

See More

Key Turning Points

3rd Resistance Point 58.31
2nd Resistance Point 57.73
1st Resistance Point 57.04
Last Price 56.36
1st Support Level 55.77
2nd Support Level 55.19
3rd Support Level 54.50

See More

52-Week High 127.20
Fibonacci 61.8% 99.65
Fibonacci 50% 91.13
Fibonacci 38.2% 82.62
Last Price 56.36
52-Week Low 55.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar